LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that its tumor-targeted doxorubicin conjugate, INNO-206, is delivering doxorubicin safely at doses over 4 times higher than the standard doxorubicin dose in the Company’s open-label Phase 1b safety and dose escalation clinical trial. The clinical trial is being conducted in up to 24 patients with advanced solid tumors who have failed standard therapies.
